Syndevrx, Inc. reported raising $16.3M in an amended private placement filing on March 20, 2017
Mar 22, 2017
Syndevrx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.
In The News
SynDevRx Assembles Prostate Cancer Medical Advisory Board to Oversee Drug Candidate That Targets Link Between Obesity and Prostate Cancer; The Board will provide insight and experience during the development of SDX-7320 across multiple lines of treatment
Jan 25, 2021 - PR Newswire